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Figure 1 Pedigree of family analyzed in this study. Unblackened
symbols indicate unaffected individuals, and blackened symbols in-
dicate affected individuals. Nine family members (II-7, III-2, III-3, III-
4, IV-1, IV-2, IV-3, IV-4, and IV-5) were examined in 1973.
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Partial Triplication of mtDNA in Maternally
Transmitted Diabetes Mellitus and Deafness
To the Editor:
Maternally inherited diabetes and deafness (MIDD) is a
recently recognized subtype of diabetes mellitus (DM)
that is associated with mtDNA mutations (Maassen et
al. 1997). The first mtDNA defect described for MIDD
was a deletion associated with a duplication of the
mtDNA in a family presenting DM and deafness over
three generations (Ballinger et al. 1992, 1994). Subse-
quent to this observation, a mutation in nucleotide (nt)
3243 was reported in several pedigrees presenting DM
and deafness (Reardon et al. 1992; van den Ouweland
et al. 1992; Kadowaki et al. 1993). We report a partial
tandem triplication of 9.2 kb in one member of a family
presenting MIDD associated with a tandem duplication
of 4.6 kb.
In 1966, a 44-year-old man (II-7) of Italian origin was
hospitalized for insulin-dependent DM and hearing loss.
In 1973, his nephew (III-2), who was born in 1932, was
hospitalized for non–insulin-dependent DM and deaf-
ness. At that time, the morbid association led to a study
of the pedigree (fig. 1), which showed transmission of
DM and deafness over four generations, with a total of
13 affected individuals (Kressmann 1976). Seven indi-
viduals from the pedigree (III-3, III-4, IV-1, IV-2, IV-3,
IV-4, and IV-5) were examined by clinicians. The clinical
history was the same for all affected patients: the first
manifestation was deafness, beginning at 20–30 years
of age, with a rapid and severe increase in bilateral sen-
sory hearing loss. DM developed later in the 3d decade,
and insulin was required either immediately or at a later
date. At that time, the individuals from the fourth gen-
eration, who were !20 years of age, presented no deaf-
ness or DM. No pedigree member had ptosis, ophthal-
moplegia, or muscle weakness. Recently, the maternal
inheritance pattern of DM and deafness in this family
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Figure 2 a, mtDNA of patient 1, digested with PvuII or BamHI and probed with an mtDNA probe, probe A and probe B. The mtDNA
showed additional fragments of 4.6 kb (PvuII digest) and 21.2 kb (BamHI digest), respectively, that are consistent with a partial duplication
of 4.6 kb. b, mtDNA of patient 2. A supplementary band of 25.8 kb was visualized with BamHI digestion. This band was detected after
hybridization with probe A included in the duplicated region (nts 2630–3353) and with probe B not retained in the duplicated segment (nts
7392–8351), thus ruling out circular deleted monomers or dimers. c, Digestion with EcoRI. For the control DNA, the expected fragments of
8, 7.3, and 1 kb are shown (the 1-kb band is not visualized). The mtDNA of patient 1 shows a supplementary band of 12.6 kb labeled with
probe A but not with probe B, corresponding to the partially duplicated molecule. For patient 2, one additional band of 17.2 kb was evidenced
with probe A but not with probe B. This is interpreted as a new mtDNA species harboring a tandem repetition of the 4.6-kb duplicated sequence
of patient 1.
was noticed, and three patients were examined again by
clinicians. Patient 1 (IV-1), 40 years old, and patient 2
(III-1), 65 years old, presented severe deafness and DM
that, with time, required insulin. Patient 3 (IV-2), 36
years old, had moderate bilateral sensory hearing loss
and subnormal glucose tolerance.
Histopathological studies of the skeletal muscle biopsy
specimens from patients 1 and 2 showed no ragged red
fibers, a complex IV enzymatic deficiency in a few fi-
bers, and very limited lipid storage on electron micros-
copy. Neither mitochondrial hyperplasia nor inclusions
were observed. No abnormalities were observed for
patient 3.
Total DNA was extracted from the muscle biopsy
specimens and blood of the three patients. The search
for the mtDNA mutation in the tRNAleu(UUR) gene at nt
3243 was performed in accordance with a protocol de-
scribed elsewhere (Ciafaloni et al. 1991). For Southern
blotting, 5 mg of total muscle DNA and 10 mg of blood
DNA were digested with restriction enzyme PvuII (nt
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Figure 3 a, PCR products obtained after amplification with primers 5 and 6. A 6.8-kb band was detected in control DNA. For patient
2, two supplementary bands of 11.4 kb and 16 kb were present, thus confirming the results of the Southern blot analysis, with regard to the
existence of mtDNA molecules linked to one (duplicated species) or two (triplicated species) rearranged molecules of 4.6 kb. “M1” and “M2”
indicate the molecular-weight markers. Lane M1, Phage l, digested with HindIII. Lane M2, Raoul. Lane C, Control DNA. Lane 2, Patient 2.
b, Sequence across the duplication junction of patient 1. The sequencing of the cloned 369-bp PCR products obtained after amplification with
primers 3 and 4 showed a normal sequence for region 3274–3577. Subsequent nts corresponded exactly to region 15547–15600. The duplication
junction is a perfect direct repeat of 10 nts, located in regions 3568–3577 (ND1 gene) and 15537–15546 (Cyt b gene). The boxed region
indicates the 10-bp perfect direct repeat. The normal sequences of ND1 and Cyt b correspond to the left and right sequences, respectively. The
same 369-bp PCR products were sequenced in patients 2 and 3, and identical results were obtained.
2650), BamHI (nt 14258), or EcoRI (nts 4121, 5274,
and 12640), in accordance with the manufacturer’s rec-
ommendations; were separated by gel electrophoresis;
and were blotted onto nylon membrane (Hybond N,
Amersham). Hybridization was performed with a ran-
dom-primed 32P-labeled mtDNA probe (Lutfalla et al.
1985) and with two random-primed 32P-labeledmtDNA
probes derived from PCR products spanning nts
2630–3353 (probe A) and nts 7392–8351 (probe B).
Quantification was performed with a Phosphor Imager
(Molecular Dynamics) by scanning of the nylon filters
of the BamHI digests hybridized with probe B. PCR
analyses of the duplicated region were performed on
muscle and blood samples by use of two different cou-
ples of primers (primer 1, nts 2630–2650, 5′-GAA TGG
CTC CAC GAG GGT TC-3′, and primer 2, nts
16255–16274, 5′-CCT AGTGGGTGAGGGGTGGC-
3′; primer 3, nts 3274–3293, 5′-ACA GTC AGA GGT
TCA ATT CC-3′, and primer 4, nts 15581–15600, 5′-
GGG ACG GAT CGG AGA ATT GT-3′). Amplification
conditions were 30 cycles of 1 min at 93C, 1 min at
62C (primers 1 and 2) or at 55C (primers 3 and 4),
and 2 min at 72C, with 2.5 U of Taq polymerase (Pro-
mega). The PCR products obtained with primers 1 and
2 were analyzed with restriction enzymes BclI (nts 3658,
7657, 8591, and 11921), EcoRI (nts 4121, 5274, and
12640), EcoRV (nts 3179, 6734, and 12871), KpnI (nts
2573, 16048, and 16121), and XhoI (nt 14955). The
369-bp PCR fragment obtained after amplification with
primers 3 and 4 was cloned into the pGEM-T vector
(Promega) and was used as a template for dideoxy se-
quencing using the T7 sequencing kit (Pharmacia), in
accordance with the manufacturer’s specifications, to re-
veal the duplication junction. To amplify all length var-
iants of the mtDNA molecules (normal, duplicated, and
triplicated) in patient 2, a long PCR was performed with
a DNA thermal cycler (Robocycler, Stratagene) and the
Expand Long PCR Template PCR system (Boehringer
Mannheim), by use of the manufacturer’s recommen-
dations modified as described elsewhere (Fromenty et al.
1996). The amplification conditions were 35 cycles for
30 s at 93C, 30 s at 66C, and 17 min at 68C. The
primer pair comprised primer 5 (forward primer), nts
13949–13972, 5′-CCT ATC TAG GCC TTC TTA CGA
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Figure 4 Schematic representation showing the normal mitochondrial genome (16.6 kb), the partially duplicated mtDNA molecule (21.2
kb) found in the three patients, and the abnormal molecule harboring the triplication (25.8 kb) in patient 2. The PvuII, BamHI, and EcoRI
sites and the locations of probe A (nts 2630–3353) and probe B (nts 7392–8351) are indicated. The curved lines indicate the regions corresponding
to the EcoRI digests of 12.6 kb and 17.2 kb, for the Southern blot analysis of patient 2. Black boxes indicate the genes involved in the
rearrangement in the normal molecule and the duplicated or triplicated fragments in the rearranged genomes.
Figure 5 DNA sequences of perfect direct repeats located across
breakpoint junctions of the mtDNA reported in the literature and
showing a polypyrimidine tract (1) in the common deletion (Schon et
al. 1989); (2) in the family described here and in two other cases of
duplication/deletion associated with myopathy (Fromenty et al. 1996;
Manfredi et al. 1997); (3) in a case of duplication/deletion associated
with DM (Ballinger et al. 1992, 1994); and (4) in a duplication as-
sociated with DM and myopathy. “R,” reported as 6/8 in (4), corre-
sponds to a ratio of 13/18 if the entire imperfect direct repeat of 18
nts is considered (Dunbar et al. 1993). “R” indicates the number of
pyrimidines in the direct repeat of the light-strand DNA template.
GCC-3′, and primer 6 (reverse primer), nts 4207–4186,
5′-GTA ATG CTA GGG TGA GTG GTA G-3′.
None of the patients carried the pathogenic point mu-
tation at nt 3243. On the other hand, the results of
Southern blot analysis of muscle DNA from patients 1
and 3, digested with restriction enzymes PvuII and
BamHI, were consistent with a partial duplication of a
4.6-kb region of mtDNA that included the PvuII restric-
tion site (nt 2650) but not the BamHI site (nt 14258)
(fig. 2a). Southern blot analysis of skeletal muscle DNA
from patient 2 unexpectedly revealed an additional 25.8-
kb band on BamHI digestion (fig. 2b), which could cor-
respond to either (1) an undigested circular deletion
monomer or dimer, (2) a second, larger duplicated mol-
ecule, or (3) an additional insert of 4.6 kb corresponding
to a partially triplicated molecule. Hybridization of the
25.8-kb band with a probe not included in the dupli-
cation (probe B) ruled out a circular deletion monomer
or dimer. The possibility of a second species duplication
also was ruled out, because an abnormal band 14.6 kb
was not detected with the PvuII digest, and only one
band was obtained by PCR when primers 3 and 4 were
used. The possibility of an mtDNA triplication in patient
2 was confirmed by digestion of the DNA, with EcoRI,
which gave two additional fragments, compared with
that of the control (fig. 2c): one fragment, of 12.6 kb,
corresponded to the partial duplication also found in
patient 1, and the other, of 17.2 kb, was consistent with
an mtDNA molecule linked to two partially duplicated
molecules. The triplication was confirmed further by
means of long PCR using primers 5 and 6 (fig. 3a). PCR
analysis and sequencing showed that the breakpoint
junction was located between the ND1 gene and the
cytochrome (Cyt) b gene at a 10-bp perfect direct repeat
(fig. 3b). These results indicate the presence of three spe-
cies of mtDNAmolecules in patient 2: a normalmolecule
(16.6 kb), a rearranged molecule (21.2 kb) that contains
an additional 4.6-kb fragment corresponding to a partial
tandem duplication, and a rearranged molecule (25.8
kb) that contains two copies of the 4.6-kb fragment cor-
responding to a partial triplication (fig. 4). The propor-
tion of duplicated mtDNA in muscle was 42% for pa-
tient 1 and 61% for patient 2. The proportion of
triplicated molecules was only 6% for patient 2. In
blood, the proportion of duplicated molecules was 52%
for patient 1 and 67% for patient 2. No triplicated mol-
ecules were detected in the blood.
Partial triplication of human mtDNA is an extremely
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rare event. Only two cases have been reported previ-
ously: one in cell culture (Holt et al. 1997) and a second
identified from autopsy material from a clinically asymp-
tomatic individual (Tengan and Moraes 1998). The mo-
lecular mechanisms leading to large-scale rearrange-
ments have not been well characterized yet, and models
of slippage mispairing or illegitimate recombination
events have been proposed (Shoffner et al. 1989; Poulton
et al. 1993). Nevertheless, the origin of slippage mis-
pairing still remains elusive. Like other reported exam-
ples of large-scale rearrangements (fig. 5), our direct
repeat harbors a long polypyrimidine (L strand)/poly-
purine (H strand) sequence. We suggest that the second
direct repeat (polypyrimidine/polypurine tract) could in-
teract with the first direct repeat to form a triple helix
(H DNA) and leads thereafter to the first tandem du-
plication. The repetition of this mechanism then could
lead to the triplication.
A major cause of diabetes in DM and deafness seems
to be a decrease in ATP production in pancreatic b cells
that could be responsible for the decrease in insulin se-
cretion (Dukes et al. 1994; Gerbitz et al. 1996). Under
normal physiological conditions, the increase in blood
glucose concentration results in an increase in ATP pro-
duction in pancreatic b cells, which in turn leads to the
closure of K channels located in the cell membrane.
This closure induces a membrane depolarization and the
opening of voltage-dependent Ca2 channels. The influx
of Ca2 into b cells then stimulates insulin exocytosis.
In DM and deafness, gene defects lead to an oxydative
phosphorylation disturbance and eventually to de-
creased ATP production. The pathogenic role of dupli-
cated or triplicated mtDNA molecules in this context is
difficult to assess, because all of the mtDNA information
content is present in these rearranged molecules. In ad-
dition, some experiments have indicated a pathogenic
role only for mtDNA deletions (Manfredi et al. 1997).
Nevertheless, like others (Dunbar et al. 1993), we have
not detected any deleted molecules, and we cannot ex-
clude a possible respiratory-chain impairment secondary
to duplicated or triplicated molecules. Indeed, an in-
crease in lactate production in cell cultures that harbor
duplicated and triplicated mtDNA has been demon-
strated (Holt et al. 1997).
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Reply to Inglehearn
To the Editor:
In our article “Localization of a Novel X-Linked Pro-
gressive Cone Dystrophy Gene to Xq27: Evidence for
Genetic Heterogeneity” (Bergen and Pinckers 1997), we
presented evidence favoring a location, on Xq27, for a
cone dystrophy gene. This localization is questioned by
Dr. Inglehearn (1998) in his letter “LOD Scores, Loca-
tion Scores, and X-Linked Cone Dystrophy.” Although
Dr. Inglehearn makes a good (methodological) point, we
feel that the majority of his criticism is not justified.
Clearly, as Dr. Inglehearn states correctly, figure 2 in
our previous article (Bergen and Pinckers 1997) shows
a picture of the multipoint location scores rather than
of the multipoint LOD scores. Although the presentation
of location scores instead of multipoint LOD scores is
not wrong in itself, it is rather unconventional and there-
fore confusing. Thus, we agree that, with regard to a
multipoint location score of 10.8, the calculated mul-
tipoint LOD score is indeed 2.35. Obviously, for X-chro-
mosomal disorders, the latter score is still considered to
be significant.
Subsequently, Dr. Inglehearn calculates, on the basis
of the data presented, multipoint (maximum?) LOD
scores of 3.38 and 2.46 at DXS998, using different
LOD-score strategies. Unfortunately, additional calcu-
lations for other markers are not given. Both these LOD
scores for DXS998 are higher than the true multipoint
LOD scores calculated by us (maximum LOD score
[Zmax] of 2.35). Thus, in our article (Bergen and Pinckers
1997), our calculation of LOD scores and our choice of
parameters were in fact very conservative. Therefore, the
assertion by Dr. Inglehearn (1998) that “these data do
indeed suggest a locus for X-linked cone dystrophy in
this region but with rather less significance than Bergen
and Pinckers have stated” (p. 900) is not justified. Most
likely, the true findings for the Zmax score at DXS998
are somewhere within the range 2.35–3.38.
Dr. Inglehearn states that a second weakness of the
article is the order and placement of markers used in the
multipoint linkage analysis. However, this assertion is
based on out-of-date and incomplete genetic maps of the
region, as indicated by the references to literature pub-
lished in 1992 and 1994 (NIH/CEPH Collaborative
Mapping Group 1992; Gyapay et al. 1994), and there-
fore is not justified. Much more recent and up-to-date
consensus maps (Dib et al. 1996) place DXS998 ∼15
cM from the distal tip of the X chromosome and at least
7 cM proximal to the red cone pigment (RCP)/green
cone pigment (GCP) gene cluster.
In addition, in our article (Bergen and Pinckers
1997), data on two additional markers, DXS297 and
DXS1123, are presented. Both DXS297 and DXS1123
reveal higher (maximum two-point) LOD scores of 2.54
and 2.60, respectively, without recombination with
COD2, but these markers are ignored in the comments
by Dr. Inglehearn. Most likely, on the basis of recom-
bination counting, haplotype analysis, and marker-to-
marker analysis, both DXS297 and DXS1123 are part
of a cosegregating haplotype, together with DXS998 and
COD2. Although DXS297 and DXS1123 are not pres-
ent on the CEPH/Ge´ne´thon consensus maps, at least two
independent reports in the literature (Richards et al.
1991; Donnelly et al. 1994) place DXS297 proximal to
the fragile X site, which is located on Xq27.3 (Dib et
al. 1996). Similar, although somewhat weaker, evidence
can be found for DXS1123. In contrast, the RCP/GCP
gene cluster is located on Xq28. In conclusion, there is
